Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aclarion, Inc. ( (ACON) ) has shared an announcement.
On July 7, 2025, Aclarion, Inc. adjourned its Annual Meeting of Stockholders without conducting any business, with plans to reconvene on July 21, 2025. The adjournment aims to solicit additional votes on proposals outlined in the company’s proxy statement, with stockholders encouraged to vote by July 20, 2025. This move reflects the company’s strategic efforts to ensure comprehensive shareholder participation and decision-making.
The most recent analyst rating on (ACON) stock is a Buy with a $1.60 price target. To see the full list of analyst forecasts on Aclarion, Inc. stock, see the ACON Stock Forecast page.
More about Aclarion, Inc.
Aclarion, Inc. is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy (MRS), artificial intelligence, and a proprietary biomarker to optimize clinical treatments for low back and neck pain. The company is focused on the $134.5 billion U.S. market for these conditions and is researching AI and machine learning applications to enhance the analysis of spectroscopy data.
Average Trading Volume: 29,904
Technical Sentiment Signal: Sell
Current Market Cap: $4.34M
See more data about ACON stock on TipRanks’ Stock Analysis page.